We would love to hear your thoughts about our site and services, please take our survey here.
In principal the GLP appear to be doing a public service. However wolves in sheeps clothing comes to mind.
This at the bottom of the crowdfunding tells you all you need to know. They rely on crowdfunding. 10% goes to admin and anything unspent gets used elsewhere. So for a case that doesn't get accepted very little gets spent. Seems to me they are sing the high profile of this test to their advantage in a number of ways.
The very thing they claim to do is to safeguard public funds. I cannot for a second think how you can challenge that in this case when they invested in Oxford and our own industry to secure long term supply at a favourable rate and ensuring the highest quality. There are many, many other examples of contracts that are higher on the priority list to challenge than this one. So why is this getting so much airtime?
"10% of the funds raised will be a contribution to the general running costs of Good Law Project. We will use any surplus to develop other litigation."
I cannot wait to get to April. Once we start seeing the profits in the bank, then the stock is no longer open to such drastic emotions as we saw yesterday. Profits do not lie. Omega are producing tests and they will be sold, whether we have a large gov contract already, or it comes in the next few weeks or they get sold elsewhere. As a 2021 investment, there is no better place for your money to work for you. As a 5-10 year investment, the same. This is not firefighting a single problem this is a defining moment for an under appreciated industry.
This complete lack of transparency and secrecy is costing us a lot of added value, but it will all come out in the wash sooner or later.
Every time Omega share price and sentiment turns positive, dark forces work together to bring it back down. That speaks volumes for the longer run, and the time is running out on the opportunities for this to happen. The fact that despite everything that has been thrown at ODX, and the great secrecy and regulatory delays beyond its control, it still has the ability to keep pushing forward to the point these attacks peg us back shows that once we get the right news with no room for critique we will be away at the races.
The manufacturing capacity is the value and the long term future. We have 2 high quality covid tests that will consume that capacity for the next few years. Further down the line diagnostics will become part of our core health sector. This opens up worlds of opportunities for LTF. Omega's ability to service worldwide markets, and reputation that enables them to have close links with the likes of Mologic will stand them in a great position. Even forget the pandemic, diagnostics is only going one way.
Crazy people cannot see what is right in front of their eyes here. Yeah we all thought we would be banging out millions of tests by now back when the UK RTC was communicated, but still the LFT market is only just opening up and Covid has proved to be a much longer term problem than we would have thought back in March.
There is so much evidence out there that LTF and in particular the ABC19 and Mologic antigen test are going to play a huge part in our fight against the pandemic.
The thing with this, it clearly says in the document he posted they recommend withdrawal of legal action. There are no grounds for action. It bats away all the claims regarding performance and the ordering process. This is a contract worth £5-£10m out of a covid spend that will go into the billions. Why so much fuss? He is clearly is still making false claims that have been shut down with evidence.
Really they should just crack on with the £75m order as it's clearly the right thing to do. But they are trying to avoid any further legal issue by doing it via the prescribed route.
The companies making up the UK RTC plus a few other similar companies, are the backbone of the UK diagnostics industry. And this is far too small, under capitalised and under prepared. If we do not invest in these companies and in this industry now, we will never close this gap and protect our health against future disasters. It is absolutely critical that these companies thrive. We cannot, and they will not turn their backs on high quality high performing companies developing top of the range tests. These companies are doing exactly what they are supposed to be doing.
The attack by GLP has zero grounds. If you ask the public how they want their money managed, they will say UK spent if possible, investing in infrastructure of the future, high quality, favourable below market price. The fact it is developed with our world leading oxford scientists along with our world leading vaccine makes it a no brainer. Why are GLP not making the same noises regarding vaccines? No different. There is actually more uncertainty around vaccine procurement than this particular contract. There is political and financial interest here and that is all.
Look at the period of time it took to forward sell enough shares for the last placing. They cant do it in one day
1 They do not need cash. They have the best part of £10m available. The cape spend to get to 2m tests was under £3m. They didn't spend the Elisa upscale. They have sold tests.
2 If a placing was coming they are not going to crash the price, they would spike the price and short sell.
So in summary they don't need money and the share price movement is not pre placing pattern.
Runner- every company will try to sell their product. They have been saying this since 2013 and still no commercial product. At some point they need to deliver to back up their claims.
That DOH person whoever, this just goes to show what type of board this is that people would rather hear trash for someone like him just because it supports your positive rather than someone that actually raises some valid points for discussion whether i am right or wrong.
Anyway, will leave you too it. Enjoy your weekends stay healthy, big week next week good luck.
CS - The UK Government are not going to pay £15 a test. They are looking £5 or even lower.
I agree the private market is going to be more in that region, but all the talk here is about supplying the government.
jmfw - the point is we keep getting told they are superior. Where is the evidence? Words mean nothing. There is a world of difference from taking something from the lab to developing a quality lateral flow test.
I have not seen a single agreement licencing out Affimers to a tests developer. The existence of one of these agreements would go a very long way to building confidence.
Captain Stanley - it is highly experimental in that they have never had a CE marked product or any commercial product.
PAH00 - Clearly i invest to make money. My comment was saying that Mologic are not in this for extortionate profit. The manufacturers will not produce at cost, but they will get the design for nothing and materials at cost or close to. It is actually important that the diagnostics manufacturers make a return, a reasonable return by a social responsible return, as that is the investment in the future of the UKs diagnostics industry. Sorry but talks from AS about 120m units a month at $20 a pop was what started the hype here and that's not going to happen.
Okehurst - Yeah i think we are really getting to the business end now. If Avacta are not involved, it certainly isn't the end, there's a long way to go.
For me a company who's USP is supposed to be superior reagents should be focusing on offering reagents to other developers, let others take the risk on test development, rather than making their own test.
Okehurst - Good first point, but goes a bit down hill after that!
"The Mologic CE antigen test in its current guise won’t be good enough for MHRA approval in the U.K. so that’s out of contention."
Wrong
"Mologic may make tests for Avacta"
There is zero chance of Mologic making Avacta tests.
"It’s all down to Aptamer group vs Avacta Group who gets the U.K. sovereign biotech contract"
This is not a 2 horse race. Both of these companies are claiming to offer viable alternatives to traditional reagents, but so far there is zero evidence of these coming into commercial use. This is still highly experimental, and an unknown quantity in the industry and just because there is an urgent commercial opportunity that does not change this. The reagent is an important part of a LFT, but it doesn't make a test. There are many possible sources out there and no proven evidence that traditional reagents can be out performed.
Mologic prefer to work with Academia rather than companies pushing solutions for commercial gain. See below.
https://www.ndcn.ox.ac.uk/news/developing-diagnostics-for-covid-19
PeterP12- sorry just because we share one common investment it doesn’t mean we have to agree on all others.
I’m sorry but there is so much unsubstantiated crap posted on this BB. Zero evidence for have the stuff claimed on here can’t even say half of it is circumstantial. You don’t like me raising serious valid alarm bells but you are happy to ready all the crap that makes zero sense.
All it takes is an rns to prove me wrong and until that happens my view is as valid as anyone else’s. The fact I have zero to gain or lose financially could make my view less biased.
As for the joke on Twitter it was light hearted banter don’t be so boring
Why would I be bitter??! Just offering an alternate view. Take it or leave it
I need no reassurance the evidence is all over the place.
UK Gov are supporting build of manufacturing capacity for a standard test. Asking the likes of ODX, probably Abingdon BBI to make it for them. But instead of buying tests from those manufacturers direct, they are going to wait for Avacta to add a mark up on them and then buy them from avacta????!!!! Oh and they have to wait for avacta to miraculously complete the development of a quality test. When a proven company like Mologic will supply the test design at cost because they are more interested in beating covid than capitalisation.
Avacta have nothing to offer in this scenario. They have gone about this the wrong way. They should have offered the reagents to other developers rather than try create their own test out of greed, either that or they knew nobody would want their affimers.
No Optimers were trialed only. See the word trial.
sjpw - sorry i thought this was exactly what this thread was about.
Sorry not trolling just stating facts. Too many people finding breadcrumbs and desperately trying to find a link to Avacta.
Mologic are not using Affimers, they are using Monoclonal antibodies. Wishful thinking i am afraid.
Another example of an R&D partnership that never came to anything
It's an all too familiar looking RNS talking about billion dollar markets, promising future revenues.
So many reasons why this is already worth a lot more than 60p a share, and so many things coming that will take it significantly higher. So grateful to be able to add this morning at such a ridiculous price.
When it is announced that Omega are making the government's 2 most important tests in ABC-19 and Mologic antigen test, this will achieve it's destiny as the hottest stock of 2021 IMO.
Rubbish. How can you tell the open that early before all the mms prices are in?!?! Wouldn’t mind it though, top up day!